Mariana Silva-Carvalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariana Silva-Carvalho has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ana Filipa Sobral
Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal
1 shared publication - Andrea Cunha
UNIPRO—Oral Pathology and Rehabilitation Research Unit University Institute of Health Sciences (IUCS‐CESPU) Gandra PRD Portugal
1 shared publication Daniel José Barbosa
Associate Laboratory i4HB—Institute for Health and Bioeconomy University Institute of Health Sciences—IUCS‐CESPU Gandra Portugal
1 shared publication- Daniel José Barbosa
Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal
1 shared publication - Diana Dias da Silva
REQUIMTE/LAQV, Escola Superior de Saúde Instituto Politécnico do Porto Porto Portugal
1 shared publication - Inês Costa
Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 26 September 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (5) , e70111
Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications
Lisdexamfetamine (LDX), a prodrug of d ‐amphetamine, is widely used in the pharmacological treatment of neuropsychiatric disorders such as attention‐deficit/hyperactivity disorder (ADHD) and binge eating disorder (BED). Chemically, it consists of the amino acid lysine linked to d ‐amphetamine. Its enzymatic conversion to d ‐amphetamine sets the stage for a prolonged and controlled release, influencing its clinical profile and differentiating it from other stimulant medications. As a central nervous system stimulant, LDX primarily acts by increasing the release of neurotransmitters, particularly dopamine and noradrenaline, in the brain. Clinically, this enhanced availability of neurotransmitters is believed to contribute to improvements in attention, focus and impulse control in individuals with ADHD. The side effects of LDX include insomnia, decreased appetite, weight loss and xerostomia. This work reviews the pharmacological mechanisms, clinical applications and forensic considerations associated with its use. It is expected that clinicians, researchers and policymakers have a comprehensive understanding of the pharmacological and toxicological aspects of LDX.
- 26 September 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (5) , e70111
Open AccessMultidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications
Lisdexamfetamine (LDX), a prodrug of d ‐amphetamine, is widely used in the pharmacological treatment of neuropsychiatric disorders such as attention‐deficit/hyperactivity disorder (ADHD) and binge eating disorder (BED). Chemically, it consists of the amino acid lysine linked to d ‐amphetamine. Its enzymatic conversion to d ‐amphetamine sets the stage for a prolonged and controlled release, influencing its clinical profile and differentiating it from other stimulant medications. As a central nervous system stimulant, LDX primarily acts by increasing the release of neurotransmitters, particularly dopamine and noradrenaline, in the brain. Clinically, this enhanced availability of neurotransmitters is believed to contribute to improvements in attention, focus and impulse control in individuals with ADHD. The side effects of LDX include insomnia, decreased appetite, weight loss and xerostomia. This work reviews the pharmacological mechanisms, clinical applications and forensic considerations associated with its use. It is expected that clinicians, researchers and policymakers have a comprehensive understanding of the pharmacological and toxicological aspects of LDX.
- Top Cited PapersOpen Access
- 13 July 2025
- Published by MDPI AG in Journal of Xenobiotics
- Vol. 15 (4) , 118
Environmental Xenobiotics and Epigenetic Modifications: Implications for Human Health and Disease
Environmental xenobiotics, including heavy metals, endocrine-disrupting chemicals (EDCs), pesticides, air pollutants, nano- and microplastics, mycotoxins, and phycotoxins, are widespread compounds that pose significant risks to human health. These substances, originating from industrial and agricultural activities, vehicle emissions, and household products, disrupt cellular homeostasis and contribute to a range of diseases, including cancer and neurodegenerative diseases, among others. Emerging evidence indicates that epigenetic alterations, such as abnormal deoxyribonucleic acid (DNA) methylation, aberrant histone modifications, and altered expression of non-coding ribonucleic acids (ncRNAs), may play a central role in mediating the toxic effects of environmental xenobiotics. Furthermore, exposure to these compounds during critical periods, such as embryogenesis and early postnatal stages, can induce long-lasting epigenetic alterations that increase susceptibility to diseases later in life. Moreover, modifications to the gamete epigenome can potentially lead to effects that persist across generations (transgenerational effects). Although these modifications represent significant health risks, many epigenetic alterations may be reversible through the removal of the xenobiotic trigger, offering potential for therapeutic intervention. This review explores the relationship between environmental xenobiotics and alterations in epigenetic signatures, focusing on how these changes impact human health, including their potential for transgenerational inheritance and their potential reversibility.
- 13 July 2025
- Published by MDPI AG in Journal of Xenobiotics
- Vol. 15 (4) , 118
Top Cited PapersOpen AccessEnvironmental Xenobiotics and Epigenetic Modifications: Implications for Human Health and Disease
Environmental xenobiotics, including heavy metals, endocrine-disrupting chemicals (EDCs), pesticides, air pollutants, nano- and microplastics, mycotoxins, and phycotoxins, are widespread compounds that pose significant risks to human health. These substances, originating from industrial and agricultural activities, vehicle emissions, and household products, disrupt cellular homeostasis and contribute to a range of diseases, including cancer and neurodegenerative diseases, among others. Emerging evidence indicates that epigenetic alterations, such as abnormal deoxyribonucleic acid (DNA) methylation, aberrant histone modifications, and altered expression of non-coding ribonucleic acids (ncRNAs), may play a central role in mediating the toxic effects of environmental xenobiotics. Furthermore, exposure to these compounds during critical periods, such as embryogenesis and early postnatal stages, can induce long-lasting epigenetic alterations that increase susceptibility to diseases later in life. Moreover, modifications to the gamete epigenome can potentially lead to effects that persist across generations (transgenerational effects). Although these modifications represent significant health risks, many epigenetic alterations may be reversible through the removal of the xenobiotic trigger, offering potential for therapeutic intervention. This review explores the relationship between environmental xenobiotics and alterations in epigenetic signatures, focusing on how these changes impact human health, including their potential for transgenerational inheritance and their potential reversibility.